Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Kyowa Hakko Kirin, a Japanese pharmaceutical company, is inviting Oxford researchers to provide exploratory Expressions of Interest in selected disease areas. In the first instance they are looking for 1-2 paragraphs of non-confidential information. The deadline to submit project summaries is 31 October 2016.

Kyowa Kirin Pharmaceutical Research (KKR), Inc is a 100% owned U.S. subsidiary of Kyowa Hakko Kirin (KHK) Co., Ltd.  We would like to enrich KHK’s research product pipeline by actively seeking external research opportunities in product compounds at early stages, discovery (target identification) to pre-clinical (efficacy and safety available), and in novel technologies. 

The scope of this call is as follows:

KHK currently focuses on advancing therapeutics in the areas of oncology, immunology (inflammation, autoimmune diseases), nephrology and central nervous system (CNS, neurodegenerative diseases, etc.). KHK would be interested in opportunities for collaboration and/or licensing in the following areas:

  • Immunology: Systemic Lupus Erythematosus, rheumatoid arthritis, inflammatory bowel disease and atopic dermatitis.*
  • Oncology: T-cell lymphomas, gastric cancer, liver cancer, lung cancer and immunotherapies.**
  • Nephrology: Acute Kidney Injury, chronic kidney disease, and dialysis related complications.**
  • Central Nervous System: Parkinson’s disease.**

Each proposal will be evaluated for novelty and competitiveness of the target/MOA/pathway with a clear path to drug discovery. Investigators can expect to receive detailed feedback on the proposal from both external innovation and scientists from the relevant R&D unit. Initial feedback will be shared within 3-6 weeks from the time of receipt. 

The application process is simple to facilitate open dialogue and quickly lead to a short conversation with a KKC representative. To apply please fill out the application form and email it to Paul Whyte ( by 31 October 2016. Successful applicants will be invited to meet with the KKC team for a short one-to-one teleconference.

Successful applicants to this call will have the opportunity to have research proposals funded by KHK and to work in close collaboration with KHK scientists by forming joint research teams and working towards in-licensing goals.


*early as target identification

**in vivo efficacy data desired but not required